Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
Preliminary data from a Phase 1 dose-escalation study evaluating Daiichi Sankyo's ( OTCPK:DSNKY ) HER3-targeting antibody-drug conjugate (ADC) U3-1402 in 23 patients with metastatic EGFR mutation-positive, TKI-resistant non-small cell lung cancer (NSCLC) showed encouraging action. The re...
FiercePharma reports that, contrary to recent rumors, Daiichi Sankyo ( OTCPK:DSNKY ) is not pursuing the divestment of its over-the-counter (OTC) drugs business, known as Daiichi Sankyo Healthcare, for ~$900M. More news on: Daiichi Sankyo Company, Limited, Daiichi Sankyo Company, Limited...
The FDA's Oncologic Drugs Advisory Committee will meet tomorrow, May 14, to review and discuss two marketing applications from Daiichi Sankyo ( OTCPK:DSNKY -1.9% ). More news on: Daiichi Sankyo Company, Limited, Daiichi Sankyo Company, Limited, Healthcare stocks news, Read more ......
Introduction In this edition of the Focus on Europe series, we are having a closer look at a small-cap (110M EUR market cap) in Belgium that doesn’t even have an OTC or pink sheets listing. Its IPO in 2017 was hyped, but the share price has lost approximately 80% since then as all h...
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late...
Today's Top Stories: Lyft begins trade after pricing IPO at top of range; equities get boost from trade talks; and stock market's best quarter in 10 years. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). It's the first IPO in the ride-hailing market and the first in a string of tech companies that are p...
Bolstering its oncology push, AstraZeneca (NYSE: AZN ) has struck a deal worth up to $6.9B to sell and develop Daiichi Sankyo's ( OTCPK:DSNKY ) promising new cancer drug. More news on: AstraZeneca PLC, Daiichi Sankyo Company, Limited, Daiichi Sankyo Company, Limited, Healthcare stocks ne...
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Plac...
MUNICH , March 18, 2019 /PRNewswire/ -- ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice Late-breaking data presented at EHRA 2019, the annual ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...